Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

PURPOSE: Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Carey, Lisa A., Berry, Donald A., Cirrincione, Constance T., Barry, William T., Pitcher, Brandelyn N., Harris, Lyndsay N., Ollila, David W., Krop, Ian E., Henry, Norah Lynn, Weckstein, Douglas J., Anders, Carey K., Singh, Baljit, Hoadley, Katherine A., Iglesia, Michael, Cheang, Maggie Chon U., Perou, Charles M., Winer, Eric P., Hudis, Clifford A.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2016
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4980567/
https://ncbi.nlm.nih.gov/pubmed/26527775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.1268
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires